INFLUENCE OF TRIMETAZIDINE ON MYOCARDIAL CAPILLAROMETRIC PARAMETERS DURING DOXORUBICIN-CYCLOPHOSPHAMIDE MODE OF CHEMOTHERAPY ADMINISTRATION
Keywords:
chemotherapy, cardiotoxicity, myocardial ischemia, microcirculation, cardio-oncologyAbstract
AC-mode of chemotherapy is the gold standard of breast cancer treatment. The components of the above-mentioned mode of chemotherapy are doxorubicin and cyclophosphamide. Both drugs, in addition to a pronounced cytotoxic and cytostatic effect, also have a significant cardiotoxic potential, which is manifested by widely variable cardiac symptoms. In the present study, the impact of the AC chemotherapy regimen on the myocardial microvasculature was studied, with the simultaneous assessment of the capillary-protective properties of trimetazidine.
References
Avagimyan A., Kakturskiy L., Heshmat-Ghahdarijani K., Pogosova N., Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol. 2021. Article N: 100909. doi: 10.1016/j.cpcardiol.2021.100909.
Avagimyan A., Kakturskiy L. The impact of trimetazidine on the anthropometric parameters of doxorubicin-cyclophosphamide mode in chemotherapy-induced heart alteration. Georgian Med News. 2022;(322):158-161.
Avagimyan A.A., Mkrtchyan L.H., Gevorkyan A.A., Kononchuk N.B., Kakturskiy L.V., Djndoyan Z.T. Relationship between chemotherapy and atrial fibrillation: clinical case. Rational Pharmacotherapy in Cardiology. 2021;17(5):785-791.https://doi.org/10.20996/1819-6446-2021-10-17
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720-1729. doi: 10.1093/eurheartj/ehaa006.
Kimberly-Louise R. In Vitro Evaluation of Anthracycline-induced Cardiotoxicity and Mitigation by Perturbation of Angiotensin Signalling, Durham theses, Durham University. 2018. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/12609/.
Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;1257:181-192. doi: 10.1007/978-3-030-43032-0_15.
Avagimyan A.A., Mkrtchyan L.G., Kononchuk N.B., Kaktursky L.V., Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(6):706-712.
Kochetkova I.V., Chernykh T.M., Panyushkina G.M. An experience of trimetazidine usage in comorbidity. Russian Journal of Cardiology. 2018;(3):37-42.
Boldueva S.A., Leonova I.A., Zakharova O.V. Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina. Rational Pharmacotherapy in Cardiology. 2020;16(3):363-369. (In Russ.)https://doi.org/10.20996/1819-6446-2020-06-12
Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, Emami AH, Dehpour AR. Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemother Pharmacol. 2020;85(3):563-571. doi: 10.1007/s00280-019-04019-6.
Omole JG, Ayoka OA, Alabi QK, Adefisayo MA, Asafa MA, Olubunmi BO, Fadeyi BA. Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats. J Evid Based Integr Med. 2018;23:2156587218757649. doi: 10.1177/2156587218757649.
Albengres E., Tillement J., Le Louet H., Morin D. Trimetazidine: Experimental and Clinical Update Review. Cardiovascular Drug Review. 1998;16(4):359-390.
